ban on semaglutide Compounded Status & What Patients Should Know – PlexusDx Troubling Findings in Study of

The trade-off calculation Retatrutide produced up to 17.5% mean weight reduction at just 24 weeks in Phase 2, with some participants achieving over 24% body weight loss

Tesofensine Regulatory Status As of June 2026, tesofensine is not FDA approved in the United States for any indication

CJC-1295 No DAC + Ipamorelin 10mg

Although promising, the molecule was never brought to market due to several patients presenting with high blood pressure

Important Considerations for Lymphedema Therapists As GLP-1 medications become increasingly common, therapists should be prepared to discuss them with patients

It doesn't yet deserve clinical use outside that framework